Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life.
Login S GeorgePaul R DubersteinNancy L KeatingBenjamin BatesDivya BhagianadhHaiqun LinBiren SaraiyaSanjay GoelAyse AkincigilPublished in: Cancer (2024)
Oncologists show substantial variation in end-of-life prescribing behavior. Future research should examine why some oncologists more often continue systemic therapy at the end of life than others, the consequences of this for patient and care outcomes, and whether interventions shaping oncologist decision-making can reduce overuse of end-of-life cancer therapies.
Keyphrases
- papillary thyroid
- primary care
- decision making
- end stage renal disease
- squamous cell
- ejection fraction
- newly diagnosed
- chronic kidney disease
- palliative care
- prognostic factors
- stem cells
- case report
- type diabetes
- quality improvement
- squamous cell carcinoma
- childhood cancer
- adverse drug
- young adults
- pain management
- metabolic syndrome
- mesenchymal stem cells
- bone marrow
- drug induced
- patient reported
- replacement therapy
- health insurance
- glycemic control